Antisense targeting of Thymidylate Synthase (TS) mRNA increases TS gene transcription and TS protein: Effects on human tumor cell sensitivity to TS enzyme-inhibiting drugs

Gene Expression

Volumn 13, Issue 4-5, 2007, Pages 227-239

  Jason, Tracey L H ^a,c   Berg, Randal W ^a,b,c   Vincent, Mark D ^a,c   Koropatnick, James ^a,b,c  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Antisense oligodeoxynucleotides; Chemotherapy; Drug resistance; Run on transcription; Threshold; Thymidylate synthase

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CISPLATIN; FLOXURIDINE; MESSENGER RNA; RALTITREXED; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; DRUG INHIBITION; DRUG SENSITIVITY; EXPRESSION VECTOR; GENE ACTIVITY; GENE EXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR CELL; UPREGULATION; UTERINE CERVIX CARCINOMA;

MAMMALIA;

EID: 34347399139     PISSN: 10522166     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006780666993     Document Type: Article

References (38)

1. Aschele, C.; Debernardis, D.; Casazza, S.; Antonelli, G.; Tunesi, G.; Baldo, C.; Lionetto, R.; Maley, F.; Sobrero, A. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J. Clin. Oncol. 17:1760-1770; 1999.
2. Berg, R. W.; Ferguso, P. J.; DeMoor, J. M.; Vincent, M. D.; Koropatnick, J. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymidylate synthase: Shoot the messenger. Curr. Drug Targets 3:297-309; 2002.
3. Berg, R. W.; Ferguson, P. J.; Vincent, M. D.; Koropatnick, D. J. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther. 10:278-286; 2003.
4. Berg, R. W.; Leung, E.; Gough, S.; Morris, C.; Yao, W. P.; Wang, S. X.; Ni, J.; Krissansen, G. W. Cloning and characterization of a novel beta integrin-related cDNA coding for the protein TIED ("ten beta integrin EGF-like repeat domains") that maps to chromosome band 13q33: A divergent stand-alone integrin stalk structure. Genomics 56:169-178; 1999.
5. Berg, R. W.; Werner, M.; Ferguson, P. J.; Postenka, C.; Vincent, M.; Koropatnick, D. J.; Behrend, E. Tumor growth inhibition in vivo and G2/M cell cycle arrest induced by antisense oligodeoxynucleotide targeting thymidylate synthase. J. Pharmacol. Exp. Ther. 298:477-484; 2001.
6. Berger, S. H.; Davis, S. T.; Barbour, K. W.; Berger, F. G. The role of thymidylate synthase in the response to fluoropyrimidine-folinic acid combinations. Adv. Exp. Med. Biol. 244:59-69; 1988.
7. Berger, S. H.; Jenh, C. H.; Johnson, L. F.; Berger, F. G. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol. Pharmacol. 28:461-467; 1985.
8. Candelaria, M.; Taja-Chayeb, L.; Arce-Salinas, C.; Vidal-Millan, S.; Serrano-Olvera, A.; Duenas-Gonzalez, A. Genetic determinants of cancer drug efficacy and toxicity: Practical considerations and perspectives. Anticancer Drugs 16:923-933; 2005.
9. Chu, E.; Allegra, C. J. Mechanisms of clinical resistance to 5-fluorouracil chemotherapy. Cancer Treat. Res. 87:175-195; 1996.
10. Chu, E.; Callender, M. A.; Farrell, M. P.; Schmitz, J. C. Thymidylate synthase inhibitors as anticancer agents: From bench to bedside. Cancer Chemother. Pharmacol. 52(Suppl. 1):S80-89; 2003.
11. Chu, E.; Cogliati, T.; Copur, S. M.; Borre, A.; Voeller, D. M.; Allegra, C. J.; Segal, S. Identification of in vivo target RNA sequences bound by thymidylate synthase. Nucleic Acids Res. 24:3222-3228; 1996.
12. Curatola, A. M.; Nadal, M. S.; Schneider, R. J. Rapid degradation of AU-rich element (ARE) mRNAs is activated by ribosome transit and blocked by secondary structure at any position 5′ to the ARE. Mol. Cell. Biol. 15:6331-6340; 1995.
13. Danenberg, P. V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta 473:73-92; 1977.
14. DeMoor, J. M.; Vincent, M. D.; Collins, O. M.; Koropatnick, J. Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription. Exp. Cell Res. 243: 11-21; 1998.
15. Edler, D.; Hallstrom, M.; Johnston, P. G.; Magnusson, I.; Ragnhammar, P.; Blomgren, H. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6: 1378-1384; 2000.
16. Farrugia, D. C.; Ford, H. E.; Cunningham, D.; Danenberg, K. D.; Danenberg, P. V.; Brabender, J.; McVicar, A. D.; Aherne, G. W.; Hardcastle, A.; McCarthy, K.; Jackman, A. L. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin. Cancer Res. 9:792-801; 2003.
17. Ferguson, P. J.; Collins, O.; Dean, N. M.; DeMoor, J.; Li, C. S.; Vincent, M. D.; Koropatnick, J. Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br. J. Pharmacol. 127:1777-1786; 1999.
18. Ferguson, P. J.; DeMoor, J. M.; Vincent, M. D.; Koropatnick, J. Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br. J. Pharmacol. 134:1437-1446; 2001.
19. Flynn, J.; Berg, R. W.; Wong, T.; van Aken, M.; Vincent, M. D.; Fukushima, M.; Koropatnick, J. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol. Cancer Ther. 5:1423-1433; 2006.
20. Gmeiner, W. H. Novel chemical strategies for thymidylate synthase inhibition. Curr. Med. Chem. 12:191-202; 2005.
21. Gorlick, R.; Bertino, J. R. Drug resistance in colon cancer. Semin. Oncol. 26:606-611; 1999.
22. Hashimoto, Y.; Shiotani, T.; Eble, J. N.; Glover, J. L.; Weber, G. Increased thymidylate synthase (EC 2.1.1.45) activity in normal and neoplastic proliferation. Cancer Biochem. Biophys. 10:1-10; 1988.
23. Johnson, L. F. Posttranscriptional regulation of thymidylate synthase gene expression. J. Cell. Biochem. 54:387-392; 1994.
24. Ju, J.; Kane, S. E.; Lenz, H. J.; Danenberg, K. D.; Chu, E.; Danenberg, P. V. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidylate synthase messenger RNA. Clin. Cancer Res. 4:2229-2236; 1998.
25. Lehman, N. L. Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin. Invest. Drugs 11:1775-1787; 2002.
26. Leichman, C. G.; Lenz, H. J.; Leichman, L.; Danenberg, K.; Baranda, J.; Groshen, S.; Boswell, W.; Metzger, R.; Tan, M.; Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15:3223-3229; 1997.
27. Leichman, L.; Lenz, H. J.; Leichman, C. G.; Groshen, S.; Danenberg, K.; Baranda, J.; Spears, C. P.; Boswell, W.; Silberman, H.; Ortega, A.; et al. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial. Eur. J. Cancer 31A: 1306-1310; 1995.
28. Lin, X.; Mizunuma, N.; Chen, T.; Copur, S. M.; Maley, G. F.; Liu, J.; Maley, F.; Chu, E. In vitro selection of an RNA sequence that interacts with high affinity with thymidylate synthase. Nucleic Acids Res. 28: 4266-4274; 2000.
29. Longley, D. B.; Ferguson, P. R.; Boyer, J.; Latif, T.; Lynch, M.; Maxwell, P.; Harkin, D. P.; Johnston, P. G. Characterization of a thymidylate synthase (TS)-inducible cell line: A model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin. Cancer Res. 7:3533-3539; 2001.
30. Mirjolet, J. F.; Barberi-Heyob, M.; Merlin, J. L.; Marchal, S.; Etienne, M. C.; Milano, G.; Bey, P. Thymidylate synthase expression and activity: Relation to S-phase parameters and 5-fluorouracil sensitivity. Br. J. Cancer 78:62-68; 1998.
31. Oliveira, C. C.; McCarthy, J. E. The relationship between eukaryotic translation and mRNA stability. A short upstream open reading frame strongly inhibits translational initiation and greatly accelerates mRNA degradation in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 270:8936-8943; 1995.
32. Pestalozzi, B. C.; McGinn, C. J.; Kinsella, T. J.; Drake, J. C.; Glennon, M. C.; Allegra, C. J.; Johnston, P. G. Increased thymidylate synthase protein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. Br. J. Cancer 71:1151-1157; 1995.
33. Ploylearmsaeng, S. A.; Fuhr, U.; Jetter, A. How may anticancer chemotherapy with fluorouracil be individualised? Clin. Pharmacokinet. 45:567-592; 2006.
34. Rahman, L.; Voeller, D.; Rahman, M.; Lipkowitz, S.; Allegra, C.; Barrett, J. C.; Kaye, F. J.; Zajac-Kaye, M. Thymidylate synthase as an oncogene: A novel role for an essential DNA synthesis enzyme. Cancer Cell 5: 341-351; 2004.
35. Saga, Y.; Suzuki, M.; Mizukami, H.; Kohno, T.; Takei, Y.; Fukushima, M.; Ozawa, K. Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells. Int. J. Cancer 106:324-326; 2003.
36. Sladek, N. E.; Kollander, R.; Sreerama, L.; Kiang, D. T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: A retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 49:309-321; 2002.
37. Tai, N.; Schmitz, J. C.; Liu, J.; Lin, X.; Bailly, M.; Chen, T. M.; Chu, E. Translational autoregulation of thymidylate synthase and dihydrofolate reductase. Front. Biosci. 9:2521-2526; 2004.
38. van Triest, B.; Pinedo, H. M.; van Hensbergen, Y.; Smid, K.; Telleman, F.; Schoenmakers, P. S.; van der Wilt, C. L.; van Laar, J. A.; Noordhuis, P.; Jansen, G.; Peters, G. J. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin. Cancer Res. 5:643-654; 1999.